Immune checkpoint inhibitor (ICI) trials have demonstrated inferior effects in both p16+ and p16- HNSCC in different trials (KEYNOTE-012, KEYNOTE-048, and KEYNOTE-040). This evidence concerns the gene CDKN2A and head and neck squamous cell carcinoma.